Multistage delivery technologies: Multifunctional, interdisciplinary approaches to nanomedicine

Molecular Therapy

Volumn 24, Issue 5, 2016, Pages 849-851

  Haynes, Matthew T ^a   Huang, Leaf ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASIALOGLYCOPROTEIN RECEPTOR; DOXORUBICIN; GALACTOSE; LIPID; LIPOSOME; MESOPOROUS SILICA NANOPARTICLE; POLYGLUTAMIC ACID; SMALL INTERFERING RNA; DRUG CARRIER; NANOCARRIER; NANOPARTICLE;

DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; INTERNALIZATION; LUNG METASTASIS; NANOENCAPSULATION; NANOMEDICINE; NANOTECHNOLOGY; NOTE; PARTICLE SIZE; TUMOR ESCAPE; DRUG DOSAGE FORM COMPARISON; DRUG TRANSPORT; ENDOTHELIUM CELL; IMMUNE EVASION; IN VIVO STUDY; LIVER CELL; PHAGOCYTOSIS; PHYSICAL CHEMISTRY; HUMAN;

DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NANOPARTICLES;

EID: 84970028118     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2016.75     Document Type: Note

References (27)

1. Swenson CE, Bolcsak LE, Batist G, Guthrie THJ, Tkaczuk KH, Boxenbaum H, et al. (2003). Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anti-Cancer Drugs 14: 239-246.
2. Hu Y, Haynes MT, Wang Y, Liu F and Huang L (2013). A highly efficient synthetic vector: nonhydrodynamic delivery of DNA to hepatocyte nuclei in vivo. ACS Nano 7: 5376-5384.
3. Xu R, Zhang G, Mai J, Deng X, Segura-Ibarra V, Wu S, et al. (2016). An injectable nanoparticle generator enhances delivery of cancer therapeutics. Nat Biotechnol 34: 414-418.
4. Ferrari M (2010). Frontiers in cancer nanomedicine: directing mass transport through biological barriers. Trends Biotechnol 28: 181-188.
5. Blanco E, Shen H and Ferrari M (2015). Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol 33: 941-951.
6. Akinc A, Zumbuehl A, Goldberg M, Leshchiner ES, Busini V, Hossain N, et al. (2008). A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 26: 561-569.
7. Whitehead KA, Dorkin JR, Vegas AJ, Chang PH, Veiseh O, Matthews J, et al. (2014). Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. Nat Commun 5: 4277-4277.
8. Liu Y, Hu Y and Huang L (2014). Influence of polyethylene glycol density and surface lipid on pharmacokinetics and biodistribution of lipidcalcium-phosphate nanoparticles. Biomaterials 35: 3027-3034.
9. Klyachko NL, Haney MJ, Zhao Y, Manickam DS, Mahajan V, Suresh P, et al. (2014). Macrophages offer a paradigm switch for CNS delivery of therapeutic proteins. Nanomedicine (Lond) 9: 1403-1422.
10. Bago JR, Alfonso-Pecchio A, Okolie O, Dumitru R, Rinkenbaugh A, Baldwin A S, et al. (2016). Therapeutically engineered induced neural stem cells are tumour-homing and inhibit progression of glioblastoma. Nat Commun 7: 10593.
11. Huang X, Zhang F, Wang H, Niu G, Choi KY, Swierczewska M, et al. (2013). Mesenchymal stem cell-based cell engineering with multifunctional mesoporous silica nanoparticles for tumor delivery. Biomaterials 34: 1772-1780.
12. Lien M-Y, Liu L-C, Wang H-C, Yeh M-H, Chen C-J, Yeh S-P, et al. (2014). Safety and efficacy of pegylated liposomal doxorubicin-based adjuvant chemotherapy in patients with stage I-III triple-negative breast cancer. Anticancer Res 34: 7319-7326.
13. Haynes MT and Huang L (2014). Hepatic RNA interference: delivery by synthetic vectors. Drug Deliv Transl Res 4: 61-73.
14. Li S-D and Huang L (2009). Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim Biophys Acta 1788: 2259-2266.
15. Huang L and Liu Y (2011). In vivo delivery of RNAi with lipid-based nanoparticles. Ann Rev Biomed Eng 13: 507-530.
16. Tasciotti E, Liu X, Bhavane R, Plant K, Leonard AD, Price BK, et al. (2008). Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat Nanotechnology 3: 151-157.
17. Wong C, Stylianopoulos T, Cui J, Martin J, Chauhan VP, Jiang W, et al. (2011). Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc Natl Acad Sci USA 108: 2426-2431.
18. Serda RE, Mack A, Pulikkathara M, Zaske AM, Chiappini C, Fakhoury J, et al. (2010). Cellular association and assembly of a multi-stage delivery system. Small 6: 1329-1340.
19. Blanco E, Sangai T, Hsiao A, Ferrati S, Bai L, Liu X, et al. (2013). Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment. Cancer Lett 334: 245-252.
20. Xu R, Huang Y, Mai J, Zhang G, Guo X, Xia X, et al. (2013). Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy. Small 9: 1799-1808.
21. Tasciotti E, Godin B, Martinez JO, Chiappini C, Bhavane R, Liu X, et al. (2011). Near-infrared imaging method for the in vivo assessment of the biodistribution of nanoporous silicon particles. Mol Imaging 10: 56-68.
22. Lee SY, Ferrari M and Decuzzi P (2009). Design of bio-mimetic particles with enhanced vascular interaction. J Biomech 42: 1885-1890.
23. Love KT, Mahon KP, Levins CG, Whitehead KA, Querbes W, Dorkin JR, et al. (2010). Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci USA 107: 1864-1869.
24. Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, et al. (2013). Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 369: 819-829.
25. Nair JK, Willoughby JLS, Chan A, Charisse K, Alam MR, Wang Q, et al. (2014). Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc 136: 16958-16961.
26. Roger M, Clavreul A, Venier-Julienne M-C, Passirani C, Montero-Menei C and Menei P (2011). The potential of combinations of drug-loaded nanoparticle systems and adult stem cells for glioma therapy. Biomaterials 32: 2106-2116.
27. Young JS, Morshed RA, Kim JW, Balyasnikova IV, Ahmed AU and Lesniak MS (2014). Advances in stem cells, induced pluripotent stem cells, and engineered cells: delivery vehicles for anti-glioma therapy. Expert Opin Drug Deliv 11: 1733-1746.